The trial NCT05165446 will use image-based surveillance to perform tissue viscoelasticity assessments through novel MRE and NCT06328283 cites use of glutamine synthetase and BCL2 associated transcription factor 1 (BCLAF1) as a form of intervention and targets their measurement in the control (cirrhotic patients with no HCC) and experimental group (cirrhotic patients with early HCC). Here, BCLAF1 is linked to hepatocellular carcinoma.